The resistance to the tumor suppressive effects of COX inhibitors and COX-2 gene disruption in TRAMP mice is associated with the loss of COX expression in prostate tissue

Carcinogenesis

Volumn 29, Issue 1, 2008, Pages 120-128

  Wang, Xingya ^a   Colby, Jennifer K L ^b   Yang, Peiying ^c   Fischer, Susan M ^b   Newman, Robert A ^c   Klein, Russell S ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CANCER INHIBITION; CONTROLLED STUDY; DIET SUPPLEMENTATION; GENE DISRUPTION; GENE OVEREXPRESSION; HISTOPATHOLOGY; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTOR; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, TRANSGENIC; PROSTATE; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 38849096349     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm226     Document Type: Article

References (41)

1. Zha,S. et al. (2004) Cyclooxygenases in cancer: Progress and perspective. Cancer Lett., 215, 1-20.
2. Cao,Y. et al. (2001) Fatty acid CoA ligase 4 is up-regulated in colon adenocarcinoma. Cancer Res., 61, 8429-8434.
3. Klein,R.D. et al.. (2005) Transitional cell hyperplasia and carcinomas in urinary bladders of transgenic mice with keratin 5 promoter-driven cyclooxygenase-2 overexpression. Cancer Res., 65, 1808-1813.
4. Kismet,K. et al. (2004) Celecoxib: A potent cyclooxygenase-2 inhibitor in cancer prevention. Cancer Detect. Prev., 28, 127-142.
5. Irani,J. et al. (2002) Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk. J. Urol., 168 1985-1988.
6. Langman,M.J. et al.. (2000) Effect of anti-inflammatory drugs on overall risk of common cancer: Case-control study in general practice research database. BMJ, 320, 1642-1646.
7. Leitzmann,M.F. et al.. (2002) Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev., 11, 1108-1111.
8. Norrish,A.E. et al. (1998) Non-stetoidal anti-inflammatory drugs and prostate cancer progression. Int. J. Cancer, 77, 511-515.
9. Paganini-Hill,A. et al. (1989) Aspirin use and chronic diseases: A cohort study of the elderly. BMJ, 299, 1247-1250.
10. Garcia Rodriguez,L.A. et al. (2004) Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancer. Cancer Epidemiol. Biomarkers Prev., 13, 649-653.
11. Habel,L.A. et al. (2002) Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes Control 13, 427-434.
12. Nelson,J.E. et al. (2000) Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): Results of a case-control study. Oncol. Rep., 7, 169-170.
13. Roberts,R.O. et al. (2002) A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin. Proc., 77, 219-225.
14. Kirschenbaum,A. et al. (2000) Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology, 56, 671-676.
15. Lee,L.M. et al. (2001) Expression of cyclooxygenase-2 in prostate adeno-carcinoma and benign prostatic hyperplasia. Anticancer Res., 21, 1291-1294.
16. Madaan,S. et al. (2000) Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: Implications for prevention and treatment. BJU Int., 86, 736-741.
17. Shappell,S.B. et al. (2001) Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia, 3, 287-303.
18. Uotila,P. et al. (2001) Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol. Res., 29, 23-28.
19. Yoshimura,R. et al. (2000) Expression of cyclooxygenase-2 in prostate carcinoma. Cancer, 89, 589-596.
20. Hussain,T. et al. (2003) Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett., 191, 125-135.
21. Wang,W. et al. (2005) Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin. Cancer Res., 11 3250-3256.
22. Zha,S. et al..(2001) Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res., 61, 8617-8623.
23. Kaplan-Lefko,P.J. et al. (2003) Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 55, 219-237.
24. Greenberg,N.M. et al. (1995) Prostate cancer in a transgenic mouse. Proc. Natl Acad. Sci. USA, 92, 3439-3443.
25. Gupta,S. et al. (2004) Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res., 64, 3334-3343.
26. Narayanan,B.A. et al. (2004) Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin. Cancer Res., 10, 7727-7737.
27. Kulp,S.K. et al. (2004) 3-Phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res., 64 1444-1451.
28. Williams,C.S. et al. (2000) Celecoxib prevents tumor growth in vivo without toxicity to normal gut: Lack of correlation between in vitro and in vivo models. Cancer Res., 60, 6045-6051.
29. Morham,S.G. et al. (1995) Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell, 83, 473-482.
30. Shappell,S.B. et al. (2004) Prostate pathology of genetically engineered mice: Definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res., 64, 2270-2305.
31. Kempen,E.C. et al. (2001) Simultaneous quantification of arachidonic acid metabolites in cultured tumor cells using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. Anal. Biochem., 297, 183-190.
32. Wagner,M. et al. (2005) Resistance of prostate cancer cell lines to COX-2 inhibitor treatment. Biochem. Biophys. Res. Commun., 332, 800-807.
33. Klein,R.D. (2005) The use of genetically engineered mouse models of prostate cancer for nutrition and cancer chemoprevention research. Mutat. Res., 576, 111-119.
34. Zeng,Y. et al. (2005) Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by raloxifene, an antiestrogen with antiandrogen action, but not nimesulide, a selective cyclooxygenase-2 inhibitor. Carcinogenesis, 26, 1109-1116.
35. Patel,M.I. et al. (2005) Celecoxib inhibits prostate cancer growth: Evidence of a cyclooxygenase-2-independent mechanism. Clin. Cancer Res., 11, 1999-2007.
36. Wang,S. et al. (2003) Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell, 4, 209-221.
37. Lim,J.T. et al. (1999) Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem Pharmacol., 58, 1097-1107.
38. Subbarayan,V. et al. (2001) Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells. Cancer Res., 61, 2720-2726.
39. O'Neill,G.P. et al. (1993) Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett., 330, 156-160.
40. Subbaramaiah,K. et al. (1999) Inhibition of cyclooxygenase-2 gene expression by p53. J. Biol. Chem., 274, 10911-10915.
41. Yegnasubramanian,S. et al. (2004) Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res., 64, 1975-1986.